Disease Landscape and Forecast Insights

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 823 currently available and novel biosimilar products, detailing…

In 2024, sales of branded biologics in ophthalmology exceeded $6.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2024-2034 forecast period…

In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast…

In 2024, sales of branded biologics for endocrinology indications (insulins and antiresorptive analogues) exceeded $22 billion in the major pharmaceutical markets under study (United States, EU5,…

In 2024, sales of branded MAb biologics in neurology exceeded $12 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, the…

In 2024, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in the major market in…

In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion…

In 2024, sales of branded biologics for oncology (except G-CSFs), immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $160 billion in the major…

Vaccination programs have had a transformative impact on global public health, significantly reducing the burden of infectious diseases, lowering mortality, and improving quality of life worldwide…

The U.S. market for wet age-related macular degeneration (wet AMD) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options…

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…